%0 Journal Article %T Virology, Epidemiology and Control of SARS-CoV-2: A Perspective %J Nanomedicine Research Journal %I Tehran University of Medical Sciences %Z 2476-3489 %A Saeidi, Elnaz %A Ranjbar, Reza %A Zangoei-Fard, Soheil %A Guest, Paul C %A Sahebkar, Amirhossein %D 2021 %\ 04/01/2021 %V 6 %N 2 %P 96-104 %! Virology, Epidemiology and Control of SARS-CoV-2: A Perspective %K SARS-CoV-2 %K Pandemic %K viral infection %K Respiratory disease %K Control %R 10.22034/nmrj.2021.02.001 %X SARS-CoV-2 is a new human-infecting coronavirus, which is the causative agent of COVID-19 disease. The World Health Organization announced this disease as a pandemic on 11 March 2020. The genome of SARS-CoV-2 is ~30kb in length which encodes sixteen nonstructural and four main structural proteins. The structural spike protein enables SARS-CoV-2 to bind to host cell receptor angiotensin-converting enzyme 2 (ACE2), which leads to viral infection. COVID-19 is considered as a respiratory disease that affects just the lungs in most cases. There are no specific therapeutics or effective vaccines available to control COVID-19, which makes it a continuing threat to global public health. Consequently, the principal approach to prevent this disease is supportive care. Due to their potential to increase drug bioavailability, a number of approaches in pharmaceutical nanotechnology are currently being tested against SARS-CoV-2. This includes nano-based products designed for detection, prevention and treatment of COVID-19. Such approaches may help to control this current pandemic and pave the way for prevention and treatment of future coronavirus outbreaks. %U https://www.nanomedicine-rj.com/article_244768_9f44c0fb0a814cc7c4a507a43343b172.pdf